Remote video URL
Your peers rated this 5 stars
5-minute watch | Talk 11 of 15

ASH: Expert perspective

Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL

Dr Jason Westin
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr Jason Westin of University of Texas MD Anderson Cancer Center, Houston, TX, USA provides updates on ZUMA-7 elderly analysis, ZUMA-1 long-term follow-up and RWE evidence, all presented at ASH 2023

Read more

Talks in this series

2-minute watch | Talk 1 of 15
ASH: Expert perspective
2-minute watch
ASH: Expert perspective

ASH Day 1 Highlights

5-minute watch | Talk 2 of 15
3-minute watch | Talk 3 of 15
2-minute watch | Talk 7 of 15
2-minute watch | Talk 1 of 15
ASH: Expert perspective
2-minute watch
ASH: Expert perspective

ASH Day 1 Highlights

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.